General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content


The path from scientific breakthrough to successful pharmaceutical brand depends on mobilizing the best global resources, expertise and experience.

At Novartis, we often achieve success through close collaboration with partners who share a common vision and complementary strengths. A key Novartis priority is to build winning collaborations in the research of new medicines and vaccines.

We are actively seeking partnerships in several therapeutic areas. Please explore your area of interest.

Please fill in all mandatory fields marked with an asterisk (*)

Personal information

1. What is the nature of opportunitiy you are offering?

200 characters left

4. What is the potency of the compound in relevant in vitroassays?

200 characters left

5. What is the potency of the compound when given to animals? (Mention route of administration.)

200 characters left

6. What toxicological data are available?

7. Are clinical data available? If so, at what phase?

200 characters left

Please be aware that if you divulge information to us via this web site that is not already the subject of a filed patent application, such divulgement may be considered to be public disclosure and may jeopardaise any future patent application.

600 characters left
Information with asterisk (*) is mandatory

Information you supply to us
Except for information covered by our Privacy Policy, any communication or material you transmit to the Site by electronic mail or otherwise, including any data, questions comments,suggestions or the like is, and will be treated as non-confidential and nonproprietary. Novartis will not accept information identified as confidential until a confidentiality agreement is executed between Novartis and your organization. Any information identified as confidential sent to Novartis will be deleted without being read